According to the ESMO consensus conference [20], first-line decisions between BRAF/MEK inhibitors or ICIs should be individualized and based on performance status, organs involved, LDH level, tumor burden, tumor progression kinetics, comorbidities, patient preference, and treatment goals (short-term versus long-term benefit). This evidence concerns the gene BRAF and neoplasm.